Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has entered into an agreement to acquire around 37.76% equity shareholding of Ezerx Health Tech (EzeRx). Cost of acquisition will be Rs 28.69 crore. EzeRx is engaged in the production, marketing and distribution of non-invasive diagnostic and ancillary medical devices in and outside India.

Besides, the company has executed an additional agreement to acquire further around 4.04% equity shares in Agatsa Software (Agatsa) from existing shareholders resulting in total proposed acquisition of stake to go up to around 30.13% of Agatsa. Earlier, the company had acquired around 26.09% shares in Agatsa. Agatsa is engaged in research, development and commercialization of medical devices in the health diagnostics segment by leveraging technology and R&D capabilities.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.